China Cognition and Aging Study (COAST)

• ClinicalTrials.gov Identifier: NCT03653156
• Recruitment Status: Recruiting
• First Posted: August 31, 2018
• Last Update Posted: April 19, 2024
• Sponsor: Capital Medical University
• Collaborators: Beijing Tiantan Hospital; Beijing Chao Yang Hospital; Fu Xing Hospital, Capital Medical University; Peking Union Medical College Hospital; Peking University First Hospital; Peking University Third Hospital; Chinese PLA General Hospital; China-Japan Friendship Hospital; Beijing Geriatric Hospital; The First Affiliated Hospital of Dalian Medical University; Fujian Medical University Union Hospital; Guangzhou Psychiatric Hospital; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; First Affiliated Hospital of Guangxi Medical University; The Affiliated Hospital Of Guizhou Medical University; Handan Central Hospital; Hebei General Hospital; First Hospital of Shijiazhuang City; Tangshan Worker's Hospital; Hunan Provincial People's Hospital; Kaifeng Central Hospital; People's Hospital of Zhengzhou University; Wuhan University Zhongnan Hospital; First Affiliated Hospital of Harbin Medical University; Tongji Hospital; People's Hospital Affiliated Hubei Medical University; The Third Xiangya Hospital of Central South University; Xiangya Hospital of Central South University; The First Hospital of Jilin University; China-Japan Union Hospital, Jilin University; Subei People's Hospital of Jiangsu; Nantong University Affiliated Hospital; Mineral General Hospital, Xuzhou; Jiangxi Provincial People's Hopital; Anshan Central Hospital; The Affiliated Zhongshan Hospital of Dalian University; First Hospital of China Medical University; Baotou Central Hospital; General Hospital of Ningxia Medical University; The People's Hospital of Ningxia; The Affiliated Hospital of Qingdao University; The 960th Hospital of PLA; Qilu Hospital of Shandong University; Qilu Hospital of Shandong University (Qingdao); Shandong Provincial Hospital; Qingdao Municipal Hospital; The First Affiliated Hospital of Shanxi Medical University; Tang-Du Hospital; First Affiliated Hospital Xi'an Jiaotong University; Ruijin Hospital; RenJi Hospital; Shanghai Changzheng Hospital; Affiliated Hospital of North Sichuan Medical College; Tianjin Huanhu Hospital; Tianjin Medical University General Hospital; Traditional Chinese Medicine Hospital of Xinjiang Autonomous Region; Ningbo Medical Center Lihuili Hospital; First Affiliated Hospital of Wenzhou Medical University; First Affiliated Hospital of Zhejiang University; Shao Yifu Hospital of Zhejiang Medical University; Zhejiang Provincial People's Hospital; Daping Hospital and the Research Institute of Surgery of the Third Military Medical University; The Second Affiliated Hospital of Chongqing Medical University; The First Affiliated Hospital of Anhui Medical University; People's Hospital of Chongqing; Dongfang Hospital Beijing University of Chinese Medicine; Zigong No.1 Peoples Hospital
• Information provided by (Responsible Party): Jianping Jia, Capital Medical University

Study Description

Brief Summary:

The aim of this study is to establish and perfect the China Cognition and Aging Study (China COAST) cohort, to clarify the epidemiology, influencing factors, genetic characteristics, pathogenesis, disease characteristics and diagnosis and treatment status of dementia and its subtypes in China. It is of great significance to establish a relatively comprehensive national database of cognitive disorders, improve the clinical diagnosis and treatment level of cognitive disorders, and formulate prevention and treatment strategies for dementia. The primary aims of China COAST are as follows:

1. To use the prospective cohort to establish a large database research platform, so as to provide comprehensive epidemiological data, clinical and neuropsychological evaluation data, biological samples, and laboratory tests and imaging data.
2. To update the prevalence and incidence rate of dementia and its subtypes every 2-3 years, and clarify the conversion pattern from normal elderly to MCI and from MCI to dementia.
3. To explore the known or unknown protective and risk factors of dementia and its major subtypes (AD, VaD, other dementia).
4. To discover new pathogenic genes and susceptible genes of dementia and its major subtypes (AD and VaD), as well as new mutation sites of known pathogenic genes. To study the genetic variation, mutation and polymorphism of PSEN1, PSEN2, APP and APOE genes in dementia patients, and to understand their distribution and roles in the pathogenesis.
5. To study the biomarkers (body fluid, genetics, imaging) with diagnostic value of MCI, AD (sporadic and familial) and VaD, to define their cut-off values, and to establish prediction models.
6. To study the diagnostic criteria of cognitive normal, MCI, dementia and their subtypes (clinical and molecular subtypes) in the cohort, and to make psychological assessment scales with high sensitivity and specificity, and in line with the characteristics of Chinese people.
7. To find potentially modifiable risk factors for dementia and to study the prevention and intervention effect of non-pharmacological treatment on APOE ε4 carriers, MCI and AD or other dementia patients，which included improvements in education, nutrition, health care, and lifestyle changes. This needs a long time follow-up.
8. To explore the relationship between dementia as well as its major subtype AD and cerebral and systemetic circulatory disorders (for example, mixed dmentia), as well as potential therapeutic strategies.
9. To carry out investigation and researches about dementia related education, improve the awareness of dementia, and strengthen the management of dementia.
10. To investigate the level of stigma and discrimination and its influencing factors in patients with Alzheimer's disease and their caregivers.

Condition or disease
Mild Cognitive Impairment(MCI); Alzheimer Disease, Late Onset; Familial Alzheimer Disease (FAD); Vascular Dementia (VaD); Normal Control; Non-Alzheimer Degenerative Dementia

Detailed Description:

This study involved participants including Mild cognitive impairment (MCI) and its subtypes、Sporadic Alzheimer's disease (SAD)、 Familial Alzheimer's disease (FAD)、Vascular dementia (VaD)、Normal control in community population and hospital population. Research contents are as follow:

1. Through the collection of basic demographic information and clinical data from the multi-center cohort, we will calculate the prevalence and incidence rate of AD, VaD, other dementia (mixed dementia, FTD, DLB, PDD, alcohol dementia, hydrocephalus dementia, post-traumatic dementia, etc.), and update the numbers every 1-2 years.
2. To clarify the conversion pattern from normal elderly to MCI and from MCI to dementia. Through the collection and analysis of current medical history, past history, family history, living habits, drug use, physical examination and other information, we will explore the protective and risk factors of dementia and its main subtypes (AD, VaD, Other dementia), including age, gender, education level, rural/urban, marital status, parental dementia history, dietary habbit, blood pressure, drinking, smoking, diabetes, hyperlipidemia, cerebrovascular disease, heart disease, depression, hearing impairment, exercise habits (Tai chi, etc.), dementia specialist influence on patients, occupation, BMI, lifestyle changes, air pollution, head injury , social contact, low-income, and other unknown protective or risk factors. To investigate the role of ApoE gene, especially ApoEε4 in the disease onset and development, and to explore the non-pharmacological interventions For the study purpose we do follow-up every 2or 3 years.
3. By using exome sequencing, GWAS, WGS and other methods, we will search for new mutations of known pathogenic genes (APP, PSEN1, PSEN2) of AD in China, find new pathogenic genes and susceptible genes of dementia and its main subtypes (AD and VaD), and understand their distribution. We will explore the independent and combined effect of susceptibility gene variation on the risk of illness in Chinese AD population, and to obtain the key mutation sites that have a clear relationship with the incidence of AD. We will do regular follow up visits for the FAD members with new mutations of pathogenic genes, and clarify the important role of new mutations of pathogenic genes during the onset and progression of AD.
4. We will collect the biofluids (blood, cerebrospinal fluid, urine, etc.) and 18F-FDG / 11C-PIB PET/MR multimodal imaging data from people with normal cognition, MCI, AD (sporadic and familial) and VaD, and conduct regular follow up. Discover and verify the SAD related susceptible gene and FAD related pathogenic gene mutation. Through analyzing the imaging data (such as MRI brain regional volume, 18F-FDG PET and cortical Aβ load), cerebrospinal fluid and plasma markers (such as Aβ, T-tau and P-tau) and clinical features (such as psychiatric symptoms and age of onset), we will develop gene chip with high sensitivity and high specificity for early screening of dementia; develop diagnostic kits for biofluid markers (blood and cerebrospinal fluid); determine imaging cut-off values at all stages of dementia in Chinese people. We will do correlation analysis to establish early diagnosis and risk prediction model for dementia, and verify the newly developed instruments that can detect the peripheral markers of dementia patients and predict the disease progression in national large sample.
5. Through the unified and standardized neuropsychological scales, including MMSE, MoCA, CDR, NPI, ADL, etc, we will conduct investigation to subjects in baseline and follow-up period, and analyze the changes of cognitive function, ability of daily life and mental behavior symptoms in different cognitive disorders. According to the social, cultural and material changes in China in recent years, we will develop psychological assessment scales with high sensitivity and specificity, and in line with the characteristics of Chinese people. Meanwhile, on the basis of the international diagnostic standards of various subtypes of dementia, combined with the etiology, clinical manifestations, scale classification, imaging characteristics, biofluid examination, etc., we will study the novel typing method and diagnostic standards of cognitive normal, MCI, dementia and its subtypes (clinical and molecular subtypes) in Chinese population.
6. Through designing randomized controlled trials, we will study the systematic and effective NPT intervention program, including lifestyle (diet and sleep habits, smoking, drinking and social networking), health products, exercise habits, cognitive training, risk factor control, etc. We will explore the quantitative and objective evaluation criteria of NPT in AD and dementia, clarify its prevention and control efficacy on APOE ε4 carriers, MCI and dementia patients, and potential neurobiological mechanism. At the same time, we will carry out dementia related education in the community, improve the public knowledge, attention and awareness of dementia, so that patients can get early detection, early diagnosis and early intervention.
7. To explore the relationship between dementia as well as its major subtype AD and cerebral circulatory disorders (cerebral ischemic and hemorrhage diseases, cerebral arteriosclerosis and stenosis, cerebral venous diseases, etc.), especially clarify the relationship between chronic cerebral ischemia and AD, as well as its effect on AD onset, and whether or not it's risk factor for AD. Whether the therapeutic strategies for cerebral circulatory disorders should be included in the treatment of AD.

Study Design

• Study Type: Observational [Patient Registry]
• Estimated Enrollment: 100000 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Target Follow-Up Duration: 30 Years
• Official Title: China Cognition and Aging Study: a Multi-center, National-wide, Longitudinal Study in China
• Actual Study Start Date: January 1, 2000
• Estimated Primary Completion Date: January 1, 2038
• Estimated Study Completion Date: January 1, 2038

Groups and Cohorts

Group/Cohort
Mild cognitive impairment (MCI) and its subtypes; MCI cohort consists of mild cognitive impairment subjects with memory loss as predominant symptom, including amnestic mild cognitive impairment and vascular cognitive impairment no dementia, which recruit from community population and hospital population.
Sporadic Alzheimer's disease (SAD); SAD cohort consists of mild to moderate sporadic Alzheimer's disease subjects, which recruit from community population and hospital population.
Familial Alzheimer's disease (FAD); FAD cohort consists of familial Alzheimer disease subjects with known or unknown mutations, which recruit from community population and hospital population.
Vascular dementia(VaD）; VaD cohort consists of cognitive impairment subjects caused by cerebral vessel disease, including vascular dementia and mixes dementia, which recruit from community population and hospital population.
Normal control; Normal control cohort consists of cognitive normal subjects with ApoE ε4 positive or negative, which recruit from community population and hospital population.
Non-Alzheimer degenerative dementia; Frontotemporal dementia (FTD); or Parkinson's disease dementia (PDD); or dementia with Lewy bodies (DLB); or corticobasal degeneration (CBD); or dementia not otherwise specified.

Outcome Measures

Primary Outcome Measures :

1. The prevalence of MCI and AD measured using a population-based cross-sectional survey with a multistage cluster sampling design [ Time Frame: an average of 2 years ]
2. The conversion rate of normal to MCI to AD in Chinese [ Time Frame: an average of 2 years ]
3. The biomarkers for normal (pre-MCI), MCI and AD diagnosis [ Time Frame: an average of 2 years ]
   Humoral biomarkers are included Aβ42, Aβ40, phosphated tau and total tau in plasma, cerebrospinal fluid, saliva, and urine. Imaging biomarkers are included cerebral volume, glucose metabolism, amyloid and tau deposition of whole brain or hippocampus.
4. The risk factors (genetic and environmental factors) for MCI, AD and VCI at genomic and expression levels [ Time Frame: an average of 2 years ]
   Discover risk factors including genetic susceptibility loci (APOE genes and other risk genes) using gene sequencing, cardiovascular risk factors (blood glucose, cholesterol, homocysteine) using laboratory tests, and unhealthy lifestyle using questionnaire.
5. The effective non-pharmacologic treatment(NPT) intervention [ Time Frame: an average of 2 years ]
   The effective non-pharmacologic treatment(NPT) intervention- including lifestyle(diet and sleep habits, smoking, drinking and social networking), health products, exercise habits, cognitive training, risk factor control- on APOE ε4 carriers, MCI and dementia patients using questionnaire.

Biospecimen Retention:   Samples With DNA

Plasma, CSF, saliva and biopsy and autopsy

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes
• Sampling Method: Non-Probability Sample

Study Population

Mild cognitive impairment (MCI) and its subtypes、Sporadic Alzheimer's disease (SAD)、 Familial Alzheimer's disease (FAD)、Vascular dementia (VaD)、Normal control in Community population and Hospital population.

Criteria

Community population: age ≥ 55 years, male or female, with consent to participant the study.

Hospital population: subjects are all over 18 years old. Through clinical evaluation, neuropsychological test, imaging examination, blood and cerebrospinal fluid examination, etc, we will comprehensively evaluate the cognitive function and various test measures.

(1) MCI and its subtypes

Inclusion criteria:

1. Diagnosis according to 2004 Peterson's MCI criteria.
2. CDR = 0.5.
3. Memory loss is prominent, and may also be with other cognitive domain dysfunction.
4. Insidious onset, slow progress.
5. Not reaching the level of dementia.

Exclusion criteria:

1. With history of stroke and a neurological focal sign, the imaging findings are consistent with cerebral small vessal disease (Fazekas score ≥ 2 points).
2. Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.).
3. Other systemic diseases that can cause cognitive impairment (such as liver, renal and thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.).
4. Mental and neurodevelopmental retardation.
5. Contraindications to MRI.
6. Suffering from a disease that cannot be combined with cognitive examination.
7. Refuse to draw blood.
8. Refuse to sign the informed consent at baseline

(2) Sporadic Alzheimer's disease (SAD)

Inclusion criteria:

1. Dementia is diagnosed according to the criteria described by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-R). The diagnosis of AD is made using the National Institute of Neurologic and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) or National Institute on Aging and the Alzheimer's Association (NIA-AA) criteria.
2. Subjects and their informed persons can complete relevant and follow- up examinations.
3. Subjects or their authorized legal guardians sign the informed consent.

Exclusion criteria:

1. With a family history of dementia.
2. Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.).
3. Other systemic diseases that can cause cognitive impairment (such as liver, renal and thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.).
4. Mental and neurodevelopmental retardation.
5. Contraindications to MRI.
6. Suffering from a disease that cannot be combined with cognitive examination.
7. Refuse to draw blood.
8. Refuse to sign the informed consent at baseline

(3) Familial Alzheimer's disease (FAD)

Inclusion criteria:

1. Written informed consent obtained from participant or legal guardian prior to any study-related procedures.
2. Members in FAD pedigree (FAD is defined as at least two first- degree relatives suffer from AD).
3. Aged 18 (inclusive) or older.
4. At least two persons who can provide reliable information for the study. Note: Dementia is diagnosed according to the criteria described by DSM-IV-R. The diagnosis of AD is made using NINCDS-ADRDA or NIA-AA criteria. A diagnosis of MCI is assigned according to Petersen criteria.

Exclusion criteria:

1. Dementia caused by other factors such as depression, other psychiatric illnesses, thyroid dysfunction, encephalitis, multiple sclerosis, brain trauma, brain tumor, syphilis, acquired immunodeficiency syndrome (AIDS), Creutzfeldt-Jakob disease and other types of dementias such as vascular dementia (VaD), frontotemporal dementia (FTD), dementia with Lewy bodies (DLB), and Parkinson's disease dementia (PDD).
2. MRI and laboratory tests do not support or rule out a diagnosis of AD.
3. Severe circulatory, respiratory, urinary, digestive, hematopoietic diseases (such as unstable angina, uncontrollable asthma, active gastric bleeding) and cancer.
4. Participant has severe psychiatric illness or severe dementia that would interfere in completing initial and follow-up clinical assessments.
5. With history of alcohol or drug abuse.
6. Pregnant or lactating women.
7. No reliable insiders.
8. Refuse to sign the informed consent at baseline.

(4) Vascular dementia (VaD)

Inclusion criteria:

Diagnosis for probable VaD according to NINDS-AIREN diagnostic criteria.

MRI inclusion criteria:

All patients who meet clinical inclusion criteria should accept MRI scans which include an assessment of hippocampal volume.

1. multiple (≥3) supratentorial subcortical small infarcts (3-20 mm in diameter) with or without any degree of white matter lesion (WML); or moderate to severe WML (Fazekas score ≥ 2), with or without small infarction; or ≥ 1 subcortical small infarct in key regions, such as caudate nucleus, globus pallidus, or thalamus.
2. no cortical and watershed infarction, hemorrhage, hydrocephalus, or WML with specific causes (such as multiple sclerosis).
3. no hippocampus or entorhinal cortex atrophy (MTA score = 0 point).

Exclusion criteria:

1. Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.).
2. Other systemic diseases that can cause cognitive impairment (such as liver insufficiency, renal insufficiency, thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.).
3. With a history of mental illness or those with congenital mental retardation.
4. Suffering from a disease that cannot be combined with a cognitive examination.
5. Contraindications to MRI.
6. Refuse to draw blood.
7. Refuse to sign informed consent.

(5) Normal control

Inclusion criteria:

1. Aged 18 (inclusive) or above.
2. Normal MMSE and MoCA evaluations. MMSE>19 points for illiteracy, >24 points for those educated less than 7 years, >27 points for those educated equal to or more than 7 years. MoCA>13 points for illiteracy, >19 points for those educated less than 7 years, >24 points for those educated equal to or more than 7 years.

Exclusion criteria:

1. Subjects with abnormal MMSE or MoCA scores.
2. Subjects with a history of cerebral infarction, traumatic brain injury or related manifestations in MRI.
3. Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.).
4. Other systemic diseases that can cause cognitive impairment (such as liver, renal and thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.).
5. Mental and neurodevelopmental retardation.
6. Suffering from a disease that cannot be combined with a cognitive examination.
7. Contraindications to MRI.
8. Refuse to draw blood.
9. Refuse to sign the informed consent at baseline.

Contacts and Locations

Contacts

Contact: Jianping Jia, Doctor; jiajp@vip.126.com

Locations

China, Anhui

The First Affiliated Hospital of Anhui Medical University; Recruiting

Hefei, Anhui, China

Contact: Yanghua Tian, Doctor ayfytyh@126.com

China, Beijing

Beijing Geriatric Hospital; Recruiting

Changping, Beijing, China

Contact: Jihui Lv lvjihui@139.com

Beijing Chao Yang Hospital; Recruiting

Chaoyang, Beijing, China

Contact: Yue Wang, Doctor wyjoe2000@163.com

China-Japan Friendship Hospital; Recruiting

Chaoyang, Beijing, China

Contact: Dantao Peng pengdantao@medmail.com.cn

Dongfang Hospital Affiliated to Beijing University of Chinese Medicine; Recruiting

Fengtai, Beijing, China

Contact: Lanxiang Jin, Doctor jxlan2001@126.com

Chinese PLA General Hospital; Recruiting

Haidian, Beijing, China

Contact: Jianjun Jia, Doctor jiajianjun301@126.com

Fu Xing Hospital, Capital Medical University; Recruiting

Haidian, Beijing, China

Contact: Fang Li, Doctor lifangwa@sina.com

Peking University Third Hospital; Recruiting

Haidian, Beijing, China

Contact: Weizhong Xiao weizhongx@sina.com

Peking Union Medical College Hospital; Recruiting

Xicheng, Beijing, China

Contact: Jing Gao, Doctor gj107@163.com

Peking University First Hospital; Recruiting

Xicheng, Beijing, China

Contact: Zhirong Jia jiazhirong@163.com

China, Chongqing

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University; Recruiting

Yuzhong, Chongqing, China

Contact: Yanjiang Wang

Contact: Yingying Shen 123473534@qq.com

The Second Affiliated Hospital of Chongqing Medical University; Recruiting

Yuzhong, Chongqing, China

Contact: Yangmei Chen chenym1997@tom.com

China, Guangdong

Fujian Medical University Union Hospital; Recruiting

Fujian, Guangdong, China

Contact: Qinyong Ye unionqyye@163.com

Guangzhou Psychiatric Hospital; Recruiting

Guangzhou, Guangdong, China

Contact: Mouni Tang, Doctor munitang@163.com

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Recruiting

Zhongshan, Guangdong, China

Contact: Jun Liu, Doctor docliujun@126.com

China, Guangxi

First Affiliated Hospital of Guangxi Medical University; Recruiting

Nanning, Guangxi, China

Contact: Shengliang Liang ssl_1964@163.com

China, Guizhou

The Affiliated Hospital Of Guizhou Medical University; Recruiting

Guiyang, Guizhou, China

Contact: Lan Chu, Doctor chulan8999@sohu.com

China, Hebei

Handan Central Hospital; Recruiting

Handan, Hebei, China

Contact: Minchen Kan, Doctor 623090112@qq.com

First Hospital of Shijiazhuang City; Recruiting

Shijiazhuang, Hebei, China

Contact: Huiying Zhao 13323119938@163.com

Tangshan Worker's Hospital; Recruiting

Tangshan, Hebei, China

Contact: Yongqiu Li, Doctor yongqiuli@126.com

Hebei General Hospital; Recruiting

Zhijiazhuang, Hebei, China

Contact: Peiyuan Lv, Doctor peiyuanlu@163.com

China, Heilongjiang

First Affiliated Hospital of Harbin Medical University; Recruiting

Haerbin, Heilongjiang, China

Contact: Shurong Duan, Doctor duanshurongsj@163.com

China, Henan

Kaifeng Central Hospital; Recruiting

Kaifeng, Henan, China

Contact: Huanrong Yu, Doctor yrh0656@126.com

Henan Provincial People's Hospital; Recruiting

Zhengzhou, Henan, China

Contact: Jiewen Zhang, Doctor zhangjiewen9900@126.com

People's Hospital of Zhengzhou; Recruiting

Zhengzhou, Henan, China

Contact: Shuling Zhang, Doctor

Contact: Bin Zhang Zyuanyuan1121@163.com

China, Hubei

People's Hospital Affiliated Hubei Medical University; Recruiting

Wuhan, Hubei, China

Contact: Jianjun Zhang, Doctor xsssm@sina.cn

Tongji Hospital; Recruiting

Wuhan, Hubei, China

Contact: Min Zhang 4082410998@qq.com

China, Hunan

The Third Xiangya Hospital of Central South University; Recruiting

Wuhan, Hunan, China

Contact: Lu Shen shenlu2505@126.com

Wuhan University Zhongnan Hospital; Recruiting

Wuhan, Hunan, China

Contact: Hanxing Liu hanxing_liu@whu.Ed.cn

Xiangya Hospital of Central South University; Recruiting

Wuhan, Hunan, China

Contact: Qiuyun Tu, Doctor qiuyuntu@126.com

China, Jiangsu

Nantong University Affiliated Hospital; Recruiting

Nantong, Jiangsu, China

Contact: Maohong Cao, Doctor yty5532917@163.com

Subei People's Hospital of Jiangsu; Recruiting

Subei, Jiangsu, China

Contact: Jun Xu, Doctor 13611572068@126.com

Mineral General Hospital, Xuzhou; Recruiting

Xuzhou, Jiangsu, China

Contact: Liangqun Rong, Doctor rongliangqun@163.com

China, Jiangxi

Jiangxi Provincial People's Hospital; Recruiting

Nanchang, Jiangxi, China

Contact: Kunnan Zhang, Doctor zkn8@163.com

China, Jilin

China-Japan friendship Hospital of Jilin university; Recruiting

Changchun, Jilin, China

Contact: Qin Zhao, Doctor 1292860277@qq.com

The First Hospital of Jilin University; Recruiting

Changchun, Jilin, China

Contact: Li Sun, Doctor sjnksunli@163.com

China, Liaoning

Changda Hospital, Anshan; Recruiting

Anshan, Liaoning, China

Contact: Xiu Han, Doctor ashanxj@163.com

Affiliated Zhongshan hospital of Dalian university; Recruiting

Dalian, Liaoning, China

Contact: Qiang Ma, Doctor 13332258950@163.com

The First Affiliated Hospital of Dalian Medical University; Recruiting

Dalian, Liaoning, China

Contact: Cui Wang, Doctor wangc817@163.com

First Hospital of China Medical University; Recruiting

Shenyang, Liaoning, China

Contact: Yunpeng Cao, Doctor cypcmu@163.com

China, Nei Monggol

Baotou Central Hospital; Recruiting

Baotou, Nei Monggol, China

Contact: Furu Liang, Doctor ru_liang@sina.com

China, Ningxia

General Hospital of Ningxia Medical University; Recruiting

Yinchuan, Ningxia, China

Contact: Qin Zhang, Doctor nxzhangqing@aliyun.com

The People's Hospital of Ningxia; Recruiting

Yinchuan, Ningxia, China

Contact: Yongying Gao, Doctor 18169110878@163.com

China, Shandong

Qilu Hospital of Shandong University; Recruiting

Jinan, Shandong, China

Contact: Peiyan Shan, Doctor Shanpy57@163.com

Shandong Provincial Hospital; Recruiting

Jining, Shandong, China

Contact: Yifeng Du, Doctor duyifeng2013@163.com

Qilu Hospital of Shandong University (Qingdao); Recruiting

Qingdao, Shandong, China

Contact: Bin Liang, Doctor bingliangbin@163.com

QingDao Municipal Hospital; Recruiting

Qingdao, Shandong, China

Contact: Lan Tan, Doctor dr.tanlan@163.com

The Affiliated Hospital of Qingdao University; Recruiting

Qingdao, Shandong, China

Contact: Jinping Sun, Doctor sunjinping@sina.com

The 88th Hospital of PLA; Recruiting

Tai'an, Shandong, China

Contact: Jintao Zhang, Doctor zjtdoctor@126.com

China, Shanghai

Shanghai Changzheng Hospital; Recruiting

Huangpu, Shanghai, China

Contact: Jianhua Zhuang, Doctor jianhuazh11@126.com

Ruijin Hospital; Recruiting

Luwan, Shanghai, China

Contact: Gang Wang, Doctor wgneuron@hotmail.com

RenJi Hospital; Recruiting

Putong, Shanghai, China

Contact: Qun Xu, Doctor xuqun628@163.com

China, Shanxi

The First Affiliated Hospital of Shanxi Medical University; Recruiting

Taiyuan, Shanxi, China

Contact: Yuling Tian, Doctor tylzcy2018@163.com

First Affiliated Hospital Xi'an Jiaotong University; Recruiting

Xi'an, Shanxi, China

Contact: Qiumin Qu, Doctor quqiumin@medmail.com.cn

Tang-Du Hospital; Recruiting

Xi'an, Shanxi, China

Contact: Wei Zhang, Doctor zw711711@hotmail.com

China, Sichuan

Affiliated Hospital of North Sichuan Medical College; Recruiting

Nanchong, Sichuan, China

Contact: Ying Ma, Doctor yingma1314@126.com

Zigong First People's Hospital; Recruiting

Zigong, Sichuan, China

Contact: Xiaoya Xu, Doctor 502687651@qq.com

China, Tianjin

Tianjin Medical University General Hospital; Recruiting

Heping, Tianjin, China

Contact: Nan Zhang, Doctor nkzhangnan@163.com

Tianjin Huanhu Hospital; Recruiting

Jinnan, Tianjin, China

Contact: Yuying Zhou, Doctor Qiying789@sina.cn

China, Xinjiang

Traditional Chinese Medicine Hospital of Xinjiang Autonomous Region; Recruiting

Urumqi, Xinjiang, China

Contact: Xinling Meng altmxl@126.com

China, Zhejiang

First Affiliated Hospital of Zhejiang University; Recruiting

Hangzhou, Zhejiang, China

Contact: Benyan Luo, Doctor luobenyan@zju.edu.cn

Shao Yifu Hospital of Zhejiang Medical University; Recruiting

Hangzhou, Zhejiang, China

Contact: Peilin Lu, Doctor lplzxa@163.com

Zhejiang Provincial People's Hospital; Recruiting

Hangzhou, Zhejiang, China

Contact: Enyan Yu yuenyan@aliyun.com

Ningbo City Medical Treatment Center Lihuili Hospital; Recruiting

Ningbo, Zhejiang, China

Contact: Guomin Xie, Doctor drxie01@qq.com

First Affiliated Hospital of Wenzhou Medical Univeristy; Recruiting

Wenzhou, Zhejiang, China

Contact: Zhen Wang Jane.wz@163.com

Sponsors and Collaborators

Capital Medical University

Beijing Tiantan Hospital

Beijing Chao Yang Hospital

Fu Xing Hospital, Capital Medical University

Peking Union Medical College Hospital

Peking University First Hospital

Peking University Third Hospital

Chinese PLA General Hospital

China-Japan Friendship Hospital

Beijing Geriatric Hospital

The First Affiliated Hospital of Dalian Medical University

Fujian Medical University Union Hospital

Guangzhou Psychiatric Hospital

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

First Affiliated Hospital of Guangxi Medical University

The Affiliated Hospital Of Guizhou Medical University

Handan Central Hospital

Hebei General Hospital

First Hospital of Shijiazhuang City

Tangshan Worker's Hospital

Hunan Provincial People's Hospital

Kaifeng Central Hospital

People's Hospital of Zhengzhou University

Wuhan University Zhongnan Hospital

First Affiliated Hospital of Harbin Medical University

Tongji Hospital

People's Hospital Affiliated Hubei Medical University

The Third Xiangya Hospital of Central South University

Xiangya Hospital of Central South University

The First Hospital of Jilin University

China-Japan Union Hospital, Jilin University

Subei People's Hospital of Jiangsu

Nantong University Affiliated Hospital

Mineral General Hospital, Xuzhou

Jiangxi Provincial People's Hopital

Anshan Central Hospital

The Affiliated Zhongshan Hospital of Dalian University

First Hospital of China Medical University

Baotou Central Hospital

General Hospital of Ningxia Medical University

The People's Hospital of Ningxia

The Affiliated Hospital of Qingdao University

The 960th Hospital of PLA

Qilu Hospital of Shandong University

Qilu Hospital of Shandong University (Qingdao)

Shandong Provincial Hospital

Qingdao Municipal Hospital

The First Affiliated Hospital of Shanxi Medical University

Tang-Du Hospital

First Affiliated Hospital Xi'an Jiaotong University

Ruijin Hospital

RenJi Hospital

Shanghai Changzheng Hospital

Affiliated Hospital of North Sichuan Medical College

Tianjin Huanhu Hospital

Tianjin Medical University General Hospital

Traditional Chinese Medicine Hospital of Xinjiang Autonomous Region

Ningbo Medical Center Lihuili Hospital

First Affiliated Hospital of Wenzhou Medical University

First Affiliated Hospital of Zhejiang University

Shao Yifu Hospital of Zhejiang Medical University

Zhejiang Provincial People's Hospital

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

The Second Affiliated Hospital of Chongqing Medical University

The First Affiliated Hospital of Anhui Medical University

People's Hospital of Chongqing

Dongfang Hospital Beijing University of Chinese Medicine

Zigong No.1 Peoples Hospital

Investigators

• Study Chair: Jianping Jia, Doctor; Xuanwu Hospital of Capital Medical University

  Study Documents (Full-Text)

Documents provided by Jianping Jia, Capital Medical University:

Study Protocol  [PDF] June 30, 2020

More Information

Additional Information:

COAST Website 

Publications of Results:

Zhou A, Jia J. A screen for cognitive assessments for patients with vascular cognitive impairment no dementia. Int J Geriatr Psychiatry. 2009 Dec;24(12):1352-7. doi: 10.1002/gps.2265.

Zhou A, Jia J. Different cognitive profiles between mild cognitive impairment due to cerebral small vessel disease and mild cognitive impairment of Alzheimer's disease origin. J Int Neuropsychol Soc. 2009 Nov;15(6):898-905. doi: 10.1017/S1355617709990816.

Bai F, Liao W, Watson DR, Shi Y, Yuan Y, Cohen AD, Xie C, Wang Y, Yue C, Teng Y, Wu D, Jia J, Zhang Z. Mapping the altered patterns of cerebellar resting-state function in longitudinal amnestic mild cognitive impairment patients. J Alzheimers Dis. 2011;23(1):87-99. doi: 10.3233/JAD-2010-101533.

Han Y, Wang J, Zhao Z, Min B, Lu J, Li K, He Y, Jia J. Frequency-dependent changes in the amplitude of low-frequency fluctuations in amnestic mild cognitive impairment: a resting-state fMRI study. Neuroimage. 2011 Mar 1;55(1):287-95. doi: 10.1016/j.neuroimage.2010.11.059. Epub 2010 Nov 28.

Lu J, Li D, Li F, Zhou A, Wang F, Zuo X, Jia XF, Song H, Jia J. Montreal cognitive assessment in detecting cognitive impairment in Chinese elderly individuals: a population-based study. J Geriatr Psychiatry Neurol. 2011 Dec;24(4):184-90. doi: 10.1177/0891988711422528.

Shi FD, Jia JP. Neurology and neurologic practice in China. Neurology. 2011 Nov 29;77(22):1986-92. doi: 10.1212/WNL.0b013e31823a0ed3.

Han Y, Jia J, Jia XF, Qin W, Wang S. Combination of plasma biomarkers and clinical data for the detection of sporadic Alzheimer's disease. Neurosci Lett. 2012 May 16;516(2):232-6. doi: 10.1016/j.neulet.2012.03.094. Epub 2012 Apr 7.

Li F, Jia XF, Jia J. The Informant Questionnaire on Cognitive Decline in the Elderly individuals in screening mild cognitive impairment with or without functional impairment. J Geriatr Psychiatry Neurol. 2012 Dec;25(4):227-32. doi: 10.1177/0891988712464822. Epub 2012 Nov 21.

Song J, Wang S, Tan M, Jia J. G1/S checkpoint proteins in peripheral blood lymphocytes are potentially diagnostic biomarkers for Alzheimer's disease. Neurosci Lett. 2012 Sep 27;526(2):144-9. doi: 10.1016/j.neulet.2012.08.020. Epub 2012 Aug 17.

Tan M, Wang S, Song J, Jia J. Combination of p53(ser15) and p21/p21(thr145) in peripheral blood lymphocytes as potential Alzheimer's disease biomarkers. Neurosci Lett. 2012 May 16;516(2):226-31. doi: 10.1016/j.neulet.2012.03.093. Epub 2012 Apr 6.

Wang F, Shu C, Jia L, Zuo X, Zhang Y, Zhou A, Qin W, Song H, Wei C, Zhang F, Hong Z, Tang M, Wang DM, Jia J. Exploration of 16 candidate genes identifies the association of IDE with Alzheimer's disease in Han Chinese. Neurobiol Aging. 2012 May;33(5):1014.e1-9. doi: 10.1016/j.neurobiolaging.2010.08.004. Epub 2010 Sep 28.

Wang S, Song J, Tan M, Albers KM, Jia J. Mitochondrial fission proteins in peripheral blood lymphocytes are potential biomarkers for Alzheimer's disease. Eur J Neurol. 2012 Jul;19(7):1015-22. doi: 10.1111/j.1468-1331.2012.03670.x. Epub 2012 Feb 16.

Xing Y, Qin W, Li F, Jia XF, Jia J. Apolipoprotein E epsilon4 status modifies the effects of sex hormones on neuropsychiatric symptoms of Alzheimer's disease. Dement Geriatr Cogn Disord. 2012;33(1):35-42. doi: 10.1159/000336600. Epub 2012 Mar 2.

Xing Y, Wei C, Chu C, Zhou A, Li F, Wu L, Song H, Zuo X, Wang F, Qin W, Li D, Tang Y, Jia XF, Jia J. Stage-specific gender differences in cognitive and neuropsychiatric manifestations of vascular dementia. Am J Alzheimers Dis Other Demen. 2012 Sep;27(6):433-8. doi: 10.1177/1533317512454712.

Li F, Wang F, Jia J. Evaluating the prevalence of dementia in hospitalized older adults and effects of comorbid dementia on patients' hospital course. Aging Clin Exp Res. 2013 Aug;25(4):393-401. doi: 10.1007/s40520-013-0068-z. Epub 2013 Jul 20.

Xing Y, Qin W, Li F, Jia XF, Jia J. Associations between sex hormones and cognitive and neuropsychiatric manifestations in vascular dementia (VaD). Arch Gerontol Geriatr. 2013 Jan-Feb;56(1):85-90. doi: 10.1016/j.archger.2012.10.003. Epub 2012 Oct 24.

Jia J, Wang F, Wei C, Zhou A, Jia X, Li F, Tang M, Chu L, Zhou Y, Zhou C, Cui Y, Wang Q, Wang W, Yin P, Hu N, Zuo X, Song H, Qin W, Wu L, Li D, Jia L, Song J, Han Y, Xing Y, Yang P, Li Y, Qiao Y, Tang Y, Lv J, Dong X. The prevalence of dementia in urban and rural areas of China. Alzheimers Dement. 2014 Jan;10(1):1-9. doi: 10.1016/j.jalz.2013.01.012. Epub 2013 Jul 18.

Jia J, Zhou A, Wei C, Jia X, Wang F, Li F, Wu X, Mok V, Gauthier S, Tang M, Chu L, Zhou Y, Zhou C, Cui Y, Wang Q, Wang W, Yin P, Hu N, Zuo X, Song H, Qin W, Wu L, Li D, Jia L, Song J, Han Y, Xing Y, Yang P, Li Y, Qiao Y, Tang Y, Lv J, Dong X. The prevalence of mild cognitive impairment and its etiological subtypes in elderly Chinese. Alzheimers Dement. 2014 Jul;10(4):439-447. doi: 10.1016/j.jalz.2013.09.008. Epub 2014 Jan 10.

Qin W, Jia X, Wang F, Zuo X, Wu L, Zhou A, Li D, Min B, Wei C, Tang Y, Xing Y, Dong X, Wang Q, Gao Y, Li Y, Jia J. Elevated plasma angiogenesis factors in Alzheimer's disease. J Alzheimers Dis. 2015;45(1):245-52. doi: 10.3233/JAD-142409.

Song H, Long H, Zuo X, Yu C, Liu B, Wang Z, Wang Q, Wang F, Han Y, Jia J. APOE Effects on Default Mode Network in Chinese Cognitive Normal Elderly: Relationship with Clinical Cognitive Performance. PLoS One. 2015 Jul 15;10(7):e0133179. doi: 10.1371/journal.pone.0133179. eCollection 2015.

Jia J, Zuo X, Jia XF, Chu C, Wu L, Zhou A, Wei C, Tang Y, Li D, Qin W, Song H, Ma Q, Li J, Sun Y, Min B, Xue S, Xu E, Yuan Q, Wang M, Huang X, Fan C, Liu J, Ren Y, Jia Q, Wang Q, Jiao L, Xing Y, Wu X; China Cognition and Aging Study (China COAST) Group. Diagnosis and treatment of dementia in neurology outpatient departments of general hospitals in China. Alzheimers Dement. 2016 Apr;12(4):446-53. doi: 10.1016/j.jalz.2015.06.1892. Epub 2015 Aug 7.

Li H, Jia J, Yang Z. Mini-Mental State Examination in Elderly Chinese: A Population-Based Normative Study. J Alzheimers Dis. 2016 May 7;53(2):487-96. doi: 10.3233/JAD-160119.

Xing Y, Tang Y, Zhao L, Wang Q, Qin W, Zhang JL, Jia J. Plasma Ceramides and Neuropsychiatric Symptoms of Alzheimer's Disease. J Alzheimers Dis. 2016 Apr 12;52(3):1029-35. doi: 10.3233/JAD-151158.

Yuan X, Han Y, Wei Y, Xia M, Sheng C, Jia J, He Y. Regional homogeneity changes in amnestic mild cognitive impairment patients. Neurosci Lett. 2016 Aug 26;629:1-8. doi: 10.1016/j.neulet.2016.06.047. Epub 2016 Jun 23.

Li D, Hu N, Yu Y, Zhou A, Li F, Jia J. Trajectories of Multidimensional Caregiver Burden in Chinese Informal Caregivers for Dementia: Evidence from Exploratory and Confirmatory Factor Analysis of the Zarit Burden Interview. J Alzheimers Dis. 2017;59(4):1317-1325. doi: 10.3233/JAD-170172.

Liu Q, Zhu Z, Teipel SJ, Yang J, Xing Y, Tang Y, Jia J. White Matter Damage in the Cholinergic System Contributes to Cognitive Impairment in Subcortical Vascular Cognitive Impairment, No Dementia. Front Aging Neurosci. 2017 Feb 27;9:47. doi: 10.3389/fnagi.2017.00047. eCollection 2017.

Jia J, Wei C, Chen S, Li F, Tang Y, Qin W, Zhao L, Jin H, Xu H, Wang F, Zhou A, Zuo X, Wu L, Han Y, Han Y, Huang L, Wang Q, Li D, Chu C, Shi L, Gong M, Du Y, Zhang J, Zhang J, Zhou C, Lv J, Lv Y, Xie H, Ji Y, Li F, Yu E, Luo B, Wang Y, Yang S, Qu Q, Guo Q, Liang F, Zhang J, Tan L, Shen L, Zhang K, Zhang J, Peng D, Tang M, Lv P, Fang B, Chu L, Jia L, Gauthier S. The cost of Alzheimer's disease in China and re-estimation of costs worldwide. Alzheimers Dement. 2018 Apr;14(4):483-491. doi: 10.1016/j.jalz.2017.12.006. Epub 2018 Feb 9.

Li J, Wu L, Tang Y, Zhou A, Wang F, Xing Y, Jia J. Differentiation of neuropsychological features between posterior cortical atrophy and early onset Alzheimer's disease. BMC Neurol. 2018 May 10;18(1):65. doi: 10.1186/s12883-018-1068-6.

Qiu Q, Shen L, Jia L, Wang Q, Li F, Li Y, Jia J. A Novel PSEN1 M139L Mutation Found in a Chinese Pedigree with Early-Onset Alzheimer's Disease Increases Abeta42/Abeta40 ratio. J Alzheimers Dis. 2019;69(1):199-212. doi: 10.3233/JAD-181291.

Jia L, Qiu Q, Zhang H, Chu L, Du Y, Zhang J, Zhou C, Liang F, Shi S, Wang S, Qin W, Wang Q, Li F, Wang Q, Li Y, Shen L, Wei Y, Jia J. Concordance between the assessment of Abeta42, T-tau, and P-T181-tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid. Alzheimers Dement. 2019 Aug;15(8):1071-1080. doi: 10.1016/j.jalz.2019.05.002.

Jia L, Fu Y, Shen L, Zhang H, Zhu M, Qiu Q, Wang Q, Yan X, Kong C, Hao J, Wei C, Tang Y, Qin W, Li Y, Wang F, Guo D, Zhou A, Zuo X, Yu Y, Li D, Zhao L, Jin H, Jia J. PSEN1, PSEN2, and APP mutations in 404 Chinese pedigrees with familial Alzheimer's disease. Alzheimers Dement. 2020 Jan;16(1):178-191. doi: 10.1002/alz.12005.

Zhao T, Quan M, Jia J. Functional Connectivity of Default Mode Network Subsystems in the Presymptomatic Stage of Autosomal Dominant Alzheimer's Disease. J Alzheimers Dis. 2020;73(4):1435-1444. doi: 10.3233/JAD-191065.

Quan M, Zhao T, Tang Y, Luo P, Wang W, Qin Q, Li T, Wang Q, Fang J, Jia J. Effects of gene mutation and disease progression on representative neural circuits in familial Alzheimer's disease. Alzheimers Res Ther. 2020 Jan 14;12(1):14. doi: 10.1186/s13195-019-0572-2.

Jia L, Xu H, Chen S, Wang X, Yang J, Gong M, Wei C, Tang Y, Qu Q, Chu L, Shen L, Zhou C, Wang Q, Zhao T, Zhou A, Li Y, Li F, Li Y, Jin H, Qin Q, Jiao H, Li Y, Zhang H, Lyu D, Shi Y, Song Y, Jia J. The APOE epsilon4 exerts differential effects on familial and other subtypes of Alzheimer's disease. Alzheimers Dement. 2020 Dec;16(12):1613-1623. doi: 10.1002/alz.12153. Epub 2020 Sep 3.

Jia L, Zhu M, Kong C, Pang Y, Zhang H, Qiu Q, Wei C, Tang Y, Wang Q, Li Y, Li T, Li F, Wang Q, Li Y, Wei Y, Jia J. Blood neuro-exosomal synaptic proteins predict Alzheimer's disease at the asymptomatic stage. Alzheimers Dement. 2021 Jan;17(1):49-60. doi: 10.1002/alz.12166. Epub 2020 Aug 10.

Han Y, Zhou A, Li F, Wang Q, Xu L, Jia J. Apolipoprotein E epsilon4 allele is associated with vascular cognitive impairment no dementia in Chinese population. J Neurol Sci. 2020 Feb 15;409:116606. doi: 10.1016/j.jns.2019.116606. Epub 2019 Dec 6.

Qiu Q, Jia L, Wang Q, Zhao L, Jin H, Li T, Quan M, Xu L, Li B, Li Y, Jia J. Identification of a novel PSEN1 Gly111Val missense mutation in a Chinese pedigree with early-onset Alzheimer's disease. Neurobiol Aging. 2020 Jan;85:155.e1-155.e4. doi: 10.1016/j.neurobiolaging.2019.05.018. Epub 2019 May 31.

Jia L, Du Y, Chu L, Zhang Z, Li F, Lyu D, Li Y, Li Y, Zhu M, Jiao H, Song Y, Shi Y, Zhang H, Gong M, Wei C, Tang Y, Fang B, Guo D, Wang F, Zhou A, Chu C, Zuo X, Yu Y, Yuan Q, Wang W, Li F, Shi S, Yang H, Zhou C, Liao Z, Lv Y, Li Y, Kan M, Zhao H, Wang S, Yang S, Li H, Liu Z, Wang Q, Qin W, Jia J; COAST Group. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study. Lancet Public Health. 2020 Dec;5(12):e661-e671. doi: 10.1016/S2468-2667(20)30185-7.

Jia L, Li F, Wei C, Zhu M, Qu Q, Qin W, Tang Y, Shen L, Wang Y, Shen L, Li H, Peng D, Tan L, Luo B, Guo Q, Tang M, Du Y, Zhang J, Zhang J, Lyu J, Li Y, Zhou A, Wang F, Chu C, Song H, Wu L, Zuo X, Han Y, Liang J, Wang Q, Jin H, Wang W, Lu Y, Li F, Zhou Y, Zhang W, Liao Z, Qiu Q, Li Y, Kong C, Li Y, Jiao H, Lu J, Jia J. Prediction of Alzheimer's disease using multi-variants from a Chinese genome-wide association study. Brain. 2021 Apr 12;144(3):924-937. doi: 10.1093/brain/awaa364.

Qin W, Zhou A, Zuo X, Jia L, Li F, Wang Q, Li Y, Wei Y, Jin H, Cruchaga C, Benitez BA, Jia J. Exome sequencing revealed PDE11A as a novel candidate gene for early-onset Alzheimer's disease. Hum Mol Genet. 2021 May 28;30(9):811-822. doi: 10.1093/hmg/ddab090.

Jia J, Zhao T, Liu Z, Liang Y, Li F, Li Y, Liu W, Li F, Shi S, Zhou C, Yang H, Liao Z, Li Y, Zhao H, Zhang J, Zhang K, Kan M, Yang S, Li H, Liu Z, Ma R, Lv J, Wang Y, Yan X, Liang F, Yuan X, Zhang J, Gauthier S, Cummings J. Association between healthy lifestyle and memory decline in older adults: 10 year, population based, prospective cohort study. BMJ. 2023 Jan 25;380:e072691. doi: 10.1136/bmj-2022-072691.

Jia J, Zhang Y, Shi Y, Yin X, Wang S, Li Y, Zhao T, Liu W, Zhou A, Jia L. A 19-Year-Old Adolescent with Probable Alzheimer's Disease. J Alzheimers Dis. 2023;91(3):915-922. doi: 10.3233/JAD-221065. Erratum In: J Alzheimers Dis. 2023;92(4):1501-1502.

Li W, Pang Y, Wang Y, Mei F, Guo M, Wei Y, Li X, Qin W, Wang W, Jia L, Jia J. Aberrant palmitoylation caused by a ZDHHC21 mutation contributes to pathophysiology of Alzheimer's disease. BMC Med. 2023 Jun 26;21(1):223. doi: 10.1186/s12916-023-02930-7.

Quan M, Wang Q, Qin W, Wang W, Li F, Zhao T, Li T, Qiu Q, Cao S, Wang S, Wang Y, Jin H, Zhou A, Fang J, Jia L, Jia J. Shared and unique effects of ApoEepsilon4 and pathogenic gene mutation on cognition and imaging in preclinical familial Alzheimer's disease. Alzheimers Res Ther. 2023 Feb 28;15(1):40. doi: 10.1186/s13195-023-01192-y.

Jia J, Ning Y, Chen M, Wang S, Yang H, Li F, Ding J, Li Y, Zhao B, Lyu J, Yang S, Yan X, Wang Y, Qin W, Wang Q, Li Y, Zhang J, Liang F, Liao Z, Wang S. Biomarker Changes during 20 Years Preceding Alzheimer's Disease. N Engl J Med. 2024 Feb 22;390(8):712-722. doi: 10.1056/NEJMoa2310168.

• Responsible Party: Jianping Jia, Chief Director, Capital Medical University
• ClinicalTrials.gov Identifier: NCT03653156
• Other Study ID Numbers: SYXWJ001
• First Posted: August 31, 2018
• Last Update Posted: April 19, 2024
• Last Verified: April 2024

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Undecided

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Alzheimer Disease; Dementia; Dementia, Vascular; Late Onset Disorders; Cognitive Dysfunction; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders; Cognition Disorders; Cerebrovascular Disorders; Intracranial Arteriosclerosis; Intracranial Arterial Diseases; Leukoencephalopathies; Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases; Cardiovascular Diseases; Disease Attributes; Pathologic Processes